This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Cardiovascular Disease Diabetes Kidney Disease 
Med Page Today
JANUARY 28, 2025
(MedPage Today) -- The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD), making it the only.
119 
Cardiovascular Diabetology
AUGUST 23, 2024
Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and a.
129 
CTVS
NOVEMBER 18, 2024
Diabetes affects millions of Americans. If managed well through proper diet and medication, those with diabetes can lead full and active lives. There are however some serious complications commonly associated with diabetes, like cardiovascular disease, kidney disease, and PAD (Peripheral Artery Disease).
HCPLive
DECEMBER 21, 2023
A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.
122 
HCPLive
JANUARY 19, 2024
Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.
111 
The New England Journal of Medicine
MARCH 28, 2025
Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
75 
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). Diabetes Care. 4 Approximately 6.7
CardiacWire
MAY 8, 2024
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2%
116 
DAIC
JANUARY 23, 2024
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Journal of the American Heart Association
DECEMBER 1, 2023
BackgroundThe relationship between resting heart rate (RHR) and the risk of end‐stage renal disease (ESRD) among those without cardiovascular disease remains unclear. These results suggest that RHR may serve as a risk factor for kidney disease in individuals without established cardiovascular disease risk factors.
75 
American College of Cardiology
MARCH 29, 2025
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.
Hypertension Journal
DECEMBER 7, 2023
ETs were shown to play important roles among others, in systemic hypertension, particularly when resistant or difficult to control, and in pulmonary hypertension, atherosclerosis, cardiac hypertrophy, subarachnoid hemorrhage, chronic kidney disease, diabetic cardiovascular disease, scleroderma, some cancers, etc.
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors.
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
CardiacWire
OCTOBER 27, 2024
It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. A JAMA analysis of 11k adults revealed that only 10.6%
59 Circulation
NOVEMBER 11, 2024
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The hemophilia cohort was slightly older (63.2[16.8]
40 
Cardiometabolic Health Congress
NOVEMBER 25, 2024
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
52 The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Journal of the American Heart Association
MARCH 25, 2025
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidney disease, and cardiovascular disease. CKM syndrome stages 3 and 4 are considered advanced.
Cardiometabolic Health Congress
AUGUST 8, 2024
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,
59 
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
100 
Circulation
NOVEMBER 11, 2024
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among
40 
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
52 
Journal of the American Heart Association
JANUARY 19, 2024
BackgroundThis study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).Methods Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])
Cardiometabolic Health Congress
AUGUST 14, 2024
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H.
72 Cardiometabolic Health Congress
JULY 12, 2023
“In addition to our new online hubs, we are continually designing live education for delivery as satellite symposia at other large conferences such as the American Heart Association or American Diabetes Association Scientific Sessions.
40 
Cardiometabolic Health Congress
JULY 25, 2023
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] 5, 6] So, it seems that once cardiovascular disease is present, then obesity may offer some degree of protection.
52 
DAIC
MAY 16, 2024
PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S.
Cardiometabolic Health Congress
SEPTEMBER 13, 2024
The European Society of Cardiology (ESC) Congress 2024 (August 30 – September 2, 2024) has wrapped up, delivering groundbreaking insights into cardiovascular diseases and related conditions. Measuring eGFR and albuminuria is recommended for assessing kidney disease in all hypertensive patients.
59 
Dr. Malcolm Kendrick
DECEMBER 8, 2023
In addition, there are links to formal risk assessment in cardiovascular disease. With bonus hyperlinks to NICE’s guidelines on hypertension in chronic kidney disease and type I diabetes and type II diabetes and on and on. There are associated guidelines on hypertension in pregnancy.
Circulation: Heart Failure
MARCH 8, 2024
The prevalence of HF risk factors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
Stroke Journal
JANUARY 30, 2025
Background:Racial disparities have been well described in cardiovascular disease. Primary outcome was ischemic stroke, while secondary outcomes were all-cause mortality, heart failure, cardiogenic shock, MACE (composite of all-cause mortality, heart failure, and ischemic stroke), and acute kidney injury (AKI).Result:After
Circulation
NOVEMBER 11, 2024
of patients had cardiovascular disease, 10.9% diabetes, and 15.5% chronic kidney disease. The results were reported as the pooled results using risk ratio (RR) and a confidence interval (CI) of 95%.Results:The
Cardiometabolic Health Congress
JULY 10, 2024
Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. A Pioneering Journey: The Life and Legacy of Dr. George L. Bakris Dr. George L. Bakris was no-nonsense, yet kind-hearted as could be.
52 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Risk factors such as smoking, chronic kidney disease, and aging can contribute to plaque formation. The gradual loss of elasticity in arterial walls and the presence of other risk factors, such as high blood pressure and diabetes, contribute to the increased risk of cardiovascular disease (CVD) observed in aging populations.
40 
Physiologically Speaking
DECEMBER 15, 2023
But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovascular diseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. a higher metabolism). The answer is yes.
52 
Physiologically Speaking
DECEMBER 15, 2023
But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovascular diseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. a higher metabolism). The answer is yes.
52 
Physiologically Speaking
FEBRUARY 26, 2024
You’ll learn: What the Scarcity Loop is and how it guides our behaviors How ultraprocessed foods hack the Scarcity Loop About a small Amazonian tribe with virtually no incidence of cardiovascular disease How to structure your diet to achieve success in our modern food environment And more! And this is important!
52 
Physiologically Speaking
MAY 3, 2024
It’s been well-established that males and females respond differently to exercise. This was also observed in the current analysis — in which 58% of the training-induced responses were different between the sexes.
95 DAIC
APRIL 4, 2024
The study, “Association of Coronary Wall Thickening and Diminished Diastolic Function in Asymptomatic, Low Cardiovascular Disease-Risk Persons Living with HIV” was published today in Radiology: Cardiothoracic Imaging , a journal of the Radiological Society of North America ( RSNA ), which issued a news summary on the study, detailed below.
Frontiers in Cardiovascular Medicine
MARCH 20, 2025
SGLT-2 inhibitors, initially developed for type 2 diabetes, demonstrate profound cardiorenal and metabolic benefits. This review synthesizes evidence from clinical trials and mechanistic studies to elucidate their roles in cardiovascular diseases, chronic kidney disease, and non-alcoholic fatty liver disease.
52 
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovascular disease in women continues to be underrepresented and undertreated.
103 
Frontiers in Cardiovascular Medicine
DECEMBER 20, 2024
BackgroundCardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases.
Cardiometabolic Health Congress
DECEMBER 17, 2024
Regular assessment of eGFR and UACR, particularly in high-risk populations such as those with diabetes or hypertension, provides crucial insights into patient health. Even small decreases in eGFRless than 60 mL/min/1.73mare associated with an increased cardiovascular risk.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content